REFERENCES
- Physicians' Desk Reference. Medical Economics Co., Inc., New Jersey 1994; 48: 2059
- Gilman A G. Goodman and Gilman's The Pharmacological Basis of Therapeutics. Pergamon Press, Inc., New York 1990
- Larsen J R., Larsen L S. Clinical features and management of poisoning due to phenytoin. Med Toxicol Adverse Drug Exp 1989; 4: 229–245
- Lou Y Q, Kuang T Y. The molecular mechanism of polymorphism of S-mephenytoin hydroxylative metabolism [abstract]. Sheng Li Ko Hsueh Chin Chan 1995; 26: 23–28
- Goldstein J A. de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4: 285–299
- Theodore W H., Newmark M E., Desai B T., et al. Disposition of mephenytoin and its metabolite, nirvanol, in epileptic patients. Neurology 1984; 34: 1100–1102
- Ellenhorn M J., Barceloux D G. Medical Toxicology Diagnosis and Treatment of Human Poisoning. Elsevier, New York 1988
- Coombs A. Novartis®, Medical Affairs Dept., 12/16/99 [personal communication]
- Troupin A S, Ojemann L M, Dodrill C B. Mephenytoin: A Reappraisal. Epilepsia 1976; 17: 403–414
- Wilmink T, Frick T W. Drug-induced pancreatitis. Drug Safety 1996; 14: 408–409
- Mephenytoin (Mesantoin®). Clinical Pharmacology Online 1999, http://www.home.po.com
- Hydantoins with valproic acid. Medi-Span Drug-Interactions (internet) 1999, http://www.home.po.com
- Kozol H. Epilepsy, treatment with new drug: 3-methyl 5,5-phenyl-ethyl-hydantoin (phenytoin). Am J Psychiatry 1946; 103: 154–157
- Jackson G. National Medical Service, 2/28/00 [personal communication]
- Chaikin P, Adir J. Unusual absorption profile of phenytoin in a massive overdose case. J Clin Pharmacol 1987; 27: 70–73
- AACT, EAPCCT. Position Statement and Practice Guidelines on the Use of Multi-Dose Activated Charcoal in the Treatment of Acute Poisoning. J Toxicol Clin Toxicol 1999; 37: 731–751